|Last Price$4.89||Day Change (%)1.88%|
|Open Price$4.80||Day Change ($)0.09|
|Day Range4.76–4.89||52-Week Range3.05–13.26|
As of Thu 12/18/2014 04:51 PM EST | USD
More Than 150 Companies Expected to Present at the 17th Annual BIO CEO & Investor Conference
Research and Markets: Intermittent Claudication - Pipeline Review, H2 2013
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.